NF2 is a distin ct entity characterized by bilateral eighthnerve schwanno tnas, other intracranial schwannotnas and meningioma s, and multiple spinal canal scliwannomas, meningioma s and gliomas. Screening ofthe entire neural axis is mandatory because of the incidence of asympt omatic lesions. MRI is the techniqu e of choice, particula rly employing contrast-enhanced, Tl -weighted sequences in multiple image plan es. ' Neuroradiology Departm ent , Ma nchester Roya l Infirmary, Manchester, Eng la nd. Reprint requests: Jame s E. Gillespie, MB, BCh, FRCR, Ncuroradio logy Department , Manc hester Royal Infirmary, Oxfo rd Road, Manchester MI 2 9WL, England . Phone: 44-161-276-4675; fax 44-161-276-8508. 102
Introduction
Neuro fibrom ato sis type 2 (NF2 ) is a rare auto somal dominant condition associ ated with a defect on chromosome 22, distin gui shing it from the more common von Recklinghau sen ' s Disease (NF l), which involves chromosome 17Y As the form er name "central neuro fibromatosis" sugges ts, the primary manifestations ofNF2 are see n in the central nerv ous sys tem with few cutaneous signs. Tabl e I comp ares the characteris tic radiolo gic mani festations of NFl and NF2 . Th e genetic, clin ical and therap eut ic aspect s of NF2 have been discussed in the three accompanying articles in thi s series (p. 91, p. 97 and p. 110). Thi s article will co ncentrate on the role of clinical imaging in the evaluation of this unfortunate but clinic ally fascinating group of patient s.
Patient s with NF2 present them sel ves in two main gro ups to the radio log ist. Mo st commonly, patient s are sent for neur al axis screening with a definite or suspe cted clinical/genetic diagnosis of NF2. Less commonly, patient s are seen with sensorineural deafness (often unil ateral, but asymmetric if bilateral) for exclusion of an acou stic neuroma/schwannoma. In thi s latter group, bilatera l acoustic tum ors or the pre sence of an eighth -nerve tic neuromas are pat hognomonic of the condition/ but the incidence of occult spinal canal tumors has recently been shown to be as high as 89%, 3making spinal canal screening mandatory. Magnetic resonance imagi ng (MR I) has now complete ly displaced comp uted tomography (CT) and mye lography as the imaging metho d of choice" because of its sensitivity, noninvasive nature and patient safety and comfort. Tabl e 2 lists the routine MR I protocol used in our institution for screening NF2 patie nts. The central component of the protocol is the use of postcontrast Tl -weighted images (Tl WI) thro ugh the bra in and entire spinal canal. T2-weighted images (T2WI) of the brain are performed at the initial imaging study to help characterize lesions and look for non-NF2-related pathology that might coinciden tally be present, but we do not always repeat this seq uence at follow-up examinat ions . We do not routinely use T2-weighted sequences in the spinal screen, but we occasionally emp loy them when intramedullary lesions are present. When fo llow ing up on an NF2 patient who has had previous acous tic schwan noma removal by the translabyrinthine route, a precontrast T l-weigh ted sca n of the petrous bones is needed because of the high signal from fat used to pack the petrous cavity, making de tection of a sma ll enhanc ing tumor remnant difficult. CT is used only occasionally in our department in NF2 patients, principally in the acute, postoperative setting to look for hematoma or to assess ventricular size.
Imaging Appearance of NF2 Lesions

Intracranial Lesions
Cranial nerve schwannomas. These can affect any cranial nerve from three to twelve. The eighth nerve is by far the commonest site of involvement, with almost 100% of patients having bilateral acoustic schwannomas at some stage of the disease course, though not necessarily synchrono usly. Trigemi nal nerve involvement is the next most common. Schwannomas are well-circumscribed, soft-tissue masses . They are usually homogeneous when sma ll but when larger can contain cysts or areas of necrosis. Calc ifica tion is very rare. Eighth-nerve lesions usually arise j ust inside the poro us aco usticus and with increasing size extend into the cerebellopontine (CP) angle cistern, giv ing rise to the so-called "ice cream on a cone" configuration.
With fur ther en largement, compression of the seventh and fifth cranial nerves might occur, alo ng with brainstem compromise. In severe cases, lower cranial nerves might be invo lved , and fourt h ven tricu lar co mpression leading to obstructive hydrocephalus. Communicating hydrocephalus caused by elevated cerebrospinal fluid (CSF) pro tein is occasionally seen. Trigeminal schwannomas . Appropriate culturesand susceptibility studies should be performed to determine the causative organism and its susceptibility to SUPRAX; however, therapy may be started whileawaiting the result s of these studies. Therapy should be adjusted, if necessary, oncethese result s areknown.
' Efficacyfor this organi smin this organsystem was studied in fewerthan10 infections.
CONTRAINDICATIONS:
In patient s with knownallergyto the cephalosporin group of antibiotics. Administerantibiotics, including SUPRAX, cautiously to anypati ent whohas demonstrated some form of allergy, parti cul arl y to drugs. Treatmentwith broad-spectrum ant ibiotics, including SUPRAX, alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium diffi cile is a primary cause of severeantibi otic-associ ated diarrhea including pseudomembranous colitis.
Pseudomembranous colitis has beenreported with the use of SUPRAX and other broadspectrum antibi otics (includi ng macrolides, semisynthetic penicillins, and cephalosporins); therefore, it is import antto considerthis diagnosis in patient s who develop diarrhea in association with the use of antibiotics. Symptoms of pseud omembranou s colitis may occur during or after antibiotic treatmentand may range in severity from mild to IIfethreatening. Mildcases of pseudomembranous colitis usuall y respond to drug discontinuation alone. In moderateto severecases, management should includefluids, electrolytes, and protein supplementation. If the colitis does not improve after the drug has been discontinued, or if thesymptomsare severe, oral vancomycin is the drug of choicefor antibiotic-associated pseudomembranous colitis produced by C. diffi cile. Other causes of colitis should be excluded. in carbamazepine pl asma concentr ations. Drug/Laboratory Test Interactions: A falsepositive reaction for ketones in the urine may occur with tests using nitroprusside but not with those using nitroferricyanide. The administration of SUPRAX may result in a false-positive reaction for glucose in the urine using Cllnit est" .. , Bened ict's solution, or Fehling's solution. It is recommended that glucose tests basedon enzymatic glucose oxidase reactions (such as Clinistix"" or Tes-Tape" :"') be used. A fal se-positive direct Coombs test has been reported during treatment with other cephalosporin antibiotics; it shoul d berecognized that a positi ve Coombs test may be dueto the drug. Carcinogenesis, Mutagenesis, Impairment of Fertility: Lifetime studiesin animals to evaluate carcinogenic pot ential have notbeen conducted. SUPRAX did not cause point mutations in bacteria or mammalian cells, DNA damage, or chromosomedamage in vitro and did not exhibit clastogenic pot ential in vivo in the mouse micronucleus test. In rats, fertilityand reproducti ve performance were notaffected by cefixime at doses up to 125 times the adult therapeutic dose. Usage in Pregnancy: Pregnan cy Category B. Reproduction studies have been performed in mice and rats at doses up to 400times the human dose and have revealedno evidenceof harmto the fetus due to SUPRAX.There are no adequate and well-controlled studies in pregnant women. Thi s drug should be used during pregnancy onl y if clearly needed. Labor and Delivery: SUPRAX has notbeenstudied for use during labor and deli very. Give onl y if clearly need ed. Nursing Mothers: It is not known whether SUPRAX is excreted in humanmil k. Consider discontinuing nur singtemporaril y during treatment. Pediatric Use: Safety and effectiveness of SUPRAX in children aged less thansix months old have not beenestabli shed. The incidence of GI adverse reaction s, including diarrhea and loosestools, in pediatric patient s receiving the suspension, was comparableto the incidence seen in adult patients receivingtablets.
ADVERSE REACTIONS:
Most adverse reactions observed in clinical trial s were of a mild and transientnature. Fi ve percent of patients in the U.S. trial s discontinuedtherapy becauseof drug-related adverse reaction s. The most common adverse reactions in U.S. trials of thetabl et formul ation were GIevents, which were reportedin 30% of adultpatients on either theBID or the QD regimen. Clinicall y mild GI sideeffects occurred in 20%of all patients, mod erate events in 9%, and severe adve rse reactions occurred in 2% of all pati ent s. Indi vidual event rat es included diarrhea 16%, loose or frequent stool s 6%, abdominal pain 3%, nausea 7%, dyspepsia 3%, and flatulence 4%. The inciden ce of GI adve rse reactions, includinq di arrhea and loose stools, in pediatric pati ents recei ving the suspension was comparable to that seen in adult patients receiving tablets. Symptoms usuall y responded to symptomatic therapy or ceased when SUPRAX was discontinued. Seve ral patients developed severe diarrh ea and/or documented pseudom embranous colitis, and a few required hospitalization. \
The following adverse reactions have been reported following the use of SUP~A X. Incidence rates were less than 1 in 50 (less than 2%), except as noted above for GI event s. 
OVERDOSAGE:
Gastric lavag e may be indi cat ed; othe rwise, no specific antidote exists. Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Adverse react ions in small num bers of healthy adult voluntee rs receiving single doses up to 2 g of SUPRAX did not differ from the profile see n in patients treated at the rec ommended doses.
" Clini test" and Cllnistix" areregistered trademarks ofAmes Di vision, MilesLaboratories, Inc. On MRI , schwa nnomas are iso-inten se on T IWI and mildl y to moderately hyperint ense on T2WI when co mpared to surro unding brain . Cystic areas and necro sis are ident ified as low or high signal areas o n TI-and T2weig hted images, respecti vely. Evidenc e ofpreviou s hemorrhage might be see n as areas of low signal on T2WI. Arachn oid cys ts are occas ionally see n in associ ation with acoustic schwanno mas and have a signa l intens ity identica l to that of CSF.
Tes-Iape
Schwann omas enha nce strongly with intrav enous gadolinium-based cont rast med ia on MRI (Fig ures I and 2) or iodinated contrast on CT. CT will dem on strate eighthnerve tum ors larger than I to 1.5 em lying approxim ately within the CP angle cistern, but purely intrameatallesions ca nnot be identified unless air is inj ected by lumba r Meningiomas. T hese are ex tra -axial, dura l-based benign tumors that can be so lita ry or multiple. Typical locati on s for menin giomas are the fal x, cerebral co nvexities, sphenoid ridge, CP angle cis tern , olfactory groove and planum sp he no ida le. Int raventricul ar me ning iomas also occ ur, most common ly invo lv ing the trigo ne of the lateral ventricle , near the choroid plex us. Me ning iomas characteris tically have a broad base at the du ral site of origin; at the periphery of the dura l base, they might spread along the d ura l surface, giv ing rise to the "dural tail" sign (Fig ure 3) . W hen they occur in the CP ang le c istern, they might ove rlie the medial end of the internal auditory meatus, bu t they on ly rarely extend inside, a configuration liken ed to a " mushroom head." Me ningio mas are ca lcified in 20 % of ca ses and might be associated with osteolyt ic or hyperostotic bone changes. En hancement is strong and usuall y homogeneou s, al-108 thou gh areas of necro sis are so metimes enco untered. On MRI, me ningiomas are iso-to slightly hy po inte nse co mpare d to grey ma tte r on T IW I and iso-to hyperinte nse on T 2WI. Me ningio mas usuall y provoke littl e or no surroundi ng edema, altho ugh on occasion extensi ve edema is seen. Th e differen t histologic var ieties of meningiom as ca nnot be distingui shed on im aging, and the enha ncement pa tte rn on MR I or CT does not correla te with tumor vascularity as dem on strated by tomograph y.
Spinal Lesions
A variety of ex tra-and intramedull ar y tum ors occ ur in NF2 . In an indivi dua l pa tient the lesion s are often multipl e , and several hi st ol o g ic typ e s m ight coexist. Sc hwanno rnas and meningiomas are the main lesions enco untered, wit h ne urofibromas occ asionally see n. Th e characteris tic intramedulla ry tum or is the ependy moma, wit h astrocytomas also occurri ng. exit forami na into an extraspinal location. Cord co mpression is common, and multiple lesion s ca n be see n throughout the entire spinal ca nal (Fig ure 4) . MRI sig nal and enhancement characteristics are simi lar to those already described for intracran ial schwa nnomas . Neurofibro mas and schwa nnomas ca nnot be distin gu ished rad iolog ically.
Menin giomas. Th ese dura l-base d lesions are most co mmonl y see n in the thoracic ca nal. Meningiom as are usually co nfined to the int raspinal compartment but occasionally extend tow ard , or eve n through , the ex it foram ina. Bone erosion might be see n. Imagin g cha rac teristics are similar to those of their intracranial counterpart s. Menin giomas, like schwannomas, might co mp ress the cord. D istingui shing these two extra medullary entities on im aging might not always be poss ible.
Ependymomas and astrocytoma s. Th ese intramedullary neoplasms are usually indisting uishable on imaging. Both might have solid and cystic co mpo nents and can be associated with syr ingo-hyd romyelia. Epe ndy mo mas tend to be bett er defined and more foc al than astrocy to mas, whic h are ofte n more diffusely infiltra ting lesion s. A single lesion located in the conus or filum ter mina le is more likely to be an ependymo ma, with sing le astrocytomas more commo n in the cervicothoracic region. Both , however, ca n occ ur at any level, when mult iple ( Figure 5 ). On MRI , both lesion s ex pand the cord and are iso-/ hyp ointen se on T I-and hyperintense on T2-weight ed imaging. Th ey might be homo-or heterogeneou s in texture, with associated are as of cyst format ion, necrosis or (in the case of ependy mo mas) hemorrhage. Co ntrast enha nce ment is essentia l to different iating so lid fro m cys tic or necrotic seg me nts and might help to distin gu ish tum oral cys t (with enha ncing margin s) from associated syrinx. 
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